Study Evaluating Pharmacovigilance Of Refacto AF

• Status: Completed
• Trial end date: 2016-10-19
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• Patients with hemophilia A of any severity already receiving or starting treatment with ReFacto AF.

Exclusion Criteria:

• Patients with Hemophilia A treated with a product other than Refacto AF.